BR112023015527A2 - Inibidores de cdk e métodos de uso destes - Google Patents
Inibidores de cdk e métodos de uso destesInfo
- Publication number
- BR112023015527A2 BR112023015527A2 BR112023015527A BR112023015527A BR112023015527A2 BR 112023015527 A2 BR112023015527 A2 BR 112023015527A2 BR 112023015527 A BR112023015527 A BR 112023015527A BR 112023015527 A BR112023015527 A BR 112023015527A BR 112023015527 A2 BR112023015527 A2 BR 112023015527A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- cdk inhibitors
- cdk
- compounds
- compositions
- Prior art date
Links
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
inibidores de cdk e métodos de uso destes. a presente invenção refere-se a novos compostos e composições farmacêuticas destes e métodos para inibir a atividade de enzimas cdk com os compostos e composições da invenção. a presente invenção refere-se ainda a, mas não está limitada a, métodos para o tratamento de distúrbios associados à sinalização de cdk com os compostos e composições da invenção.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163149095P | 2021-02-12 | 2021-02-12 | |
US202163166638P | 2021-03-26 | 2021-03-26 | |
US202163192627P | 2021-05-25 | 2021-05-25 | |
US202163250473P | 2021-09-30 | 2021-09-30 | |
US202163292337P | 2021-12-21 | 2021-12-21 | |
PCT/US2022/016114 WO2022174031A1 (en) | 2021-02-12 | 2022-02-11 | Cdk inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023015527A2 true BR112023015527A2 (pt) | 2023-11-28 |
Family
ID=82837943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023015527A BR112023015527A2 (pt) | 2021-02-12 | 2022-02-11 | Inibidores de cdk e métodos de uso destes |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4291176A1 (pt) |
JP (1) | JP2024507131A (pt) |
KR (1) | KR20230173083A (pt) |
AU (1) | AU2022219987A1 (pt) |
BR (1) | BR112023015527A2 (pt) |
CA (1) | CA3210224A1 (pt) |
CL (1) | CL2023002276A1 (pt) |
IL (1) | IL305087A (pt) |
MX (1) | MX2023009086A (pt) |
PE (1) | PE20231938A1 (pt) |
TW (1) | TW202246255A (pt) |
WO (1) | WO2022174031A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023274397A1 (zh) * | 2021-07-01 | 2023-01-05 | 上海拓界生物医药科技有限公司 | Cdk2抑制剂及其制备方法和用途 |
CN118019734A (zh) * | 2021-10-05 | 2024-05-10 | 基因泰克公司 | 环戊基吡唑cdk2抑制剂 |
WO2023072096A1 (zh) * | 2021-10-25 | 2023-05-04 | 优领医药科技(香港)有限公司 | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 |
TW202325280A (zh) * | 2021-11-09 | 2023-07-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種胺基吡唑衍生物及其製備方法和用途 |
WO2023083286A1 (en) | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
WO2023141852A1 (zh) * | 2022-01-27 | 2023-08-03 | 益方生物科技(上海)股份有限公司 | Cdk2抑制剂及其制备方法和用途 |
TW202337434A (zh) * | 2022-02-11 | 2023-10-01 | 美商傳達治療有限公司 | Cdk抑制劑及其使用方法 |
WO2023160572A1 (zh) * | 2022-02-24 | 2023-08-31 | 楚浦创制(武汉)医药科技有限公司 | 吡唑类衍生物、药物组合物及应用 |
WO2023208143A1 (zh) * | 2022-04-28 | 2023-11-02 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
WO2023244710A1 (en) * | 2022-06-16 | 2023-12-21 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
WO2024035830A1 (en) * | 2022-08-11 | 2024-02-15 | Relay Therapeutics, Inc. | Solid forms of a cdk inhibitor |
WO2024046443A1 (en) * | 2022-09-01 | 2024-03-07 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocyclic compounds as selective cdk inhibitors |
WO2024051727A1 (zh) * | 2022-09-09 | 2024-03-14 | 楚浦创制(武汉)医药科技有限公司 | 吡唑类衍生物、药物组合物及应用 |
WO2024059010A1 (en) | 2022-09-13 | 2024-03-21 | Genesis Therapeutics, Inc. | Compounds for treating cancer |
WO2024056019A1 (en) * | 2022-09-15 | 2024-03-21 | Beigene, Ltd. | Bicyclic compounds as cdk inhibitors |
WO2024066981A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制(武汉)医药科技有限公司 | 氘代吡唑类衍生物、药物组合物及应用与制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
TWI426074B (zh) * | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | 5-(2-胺基-嘧啶-4-基)-2-芳基-1h-吡咯-3-羧醯胺之製造方法 |
-
2022
- 2022-02-11 EP EP22753406.2A patent/EP4291176A1/en active Pending
- 2022-02-11 JP JP2023548258A patent/JP2024507131A/ja active Pending
- 2022-02-11 MX MX2023009086A patent/MX2023009086A/es unknown
- 2022-02-11 KR KR1020237030200A patent/KR20230173083A/ko unknown
- 2022-02-11 WO PCT/US2022/016114 patent/WO2022174031A1/en active Application Filing
- 2022-02-11 TW TW111105034A patent/TW202246255A/zh unknown
- 2022-02-11 IL IL305087A patent/IL305087A/en unknown
- 2022-02-11 PE PE2023002343A patent/PE20231938A1/es unknown
- 2022-02-11 BR BR112023015527A patent/BR112023015527A2/pt unknown
- 2022-02-11 CA CA3210224A patent/CA3210224A1/en active Pending
- 2022-02-11 AU AU2022219987A patent/AU2022219987A1/en active Pending
-
2023
- 2023-08-02 CL CL2023002276A patent/CL2023002276A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4291176A1 (en) | 2023-12-20 |
AU2022219987A1 (en) | 2023-08-10 |
CL2023002276A1 (es) | 2024-03-15 |
TW202246255A (zh) | 2022-12-01 |
MX2023009086A (es) | 2023-08-08 |
CA3210224A1 (en) | 2022-08-18 |
PE20231938A1 (es) | 2023-12-05 |
WO2022174031A1 (en) | 2022-08-18 |
KR20230173083A (ko) | 2023-12-26 |
IL305087A (en) | 2023-10-01 |
JP2024507131A (ja) | 2024-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
BR112022021854A2 (pt) | Inibidores de fosfatidilinositol 3-quinase alfa e mé-todos de uso dos mesmos | |
BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
BR112022002991A2 (pt) | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos | |
UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
BR112013021638A2 (pt) | "compostos inibidores de trk, seu uso e composições que os compreendem" | |
BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
BR112022009409A2 (pt) | Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem | |
BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
NZ756603A (en) | Selective hdac6 inhibitors | |
BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
BR112022019492A2 (pt) | Inibidores de rip1k | |
BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
BR112021006319A2 (pt) | compostos de indolinona para uso como inibidores de map4k1 | |
BR112021021826A2 (pt) | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 | |
BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
AR126447A1 (es) | INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS | |
BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença |